Sagentia selected as development partner for SetPoint Medical's novel neuromodulation device to treat chronic inflammatory disease

Sagentia's picture
Printer-friendly versionPrinter-friendly versionPDF versionPDF version

5 December 2013

Sagentia, a global technology and product development company, has been hired by SetPoint Medical to work on the development of the programming interface for a neuromodulation device. The device aims to provide patients with a lower risk and lower cost alternative to immunosuppressive drugs for the treatment of chronic inflammatory diseases.

SetPoint Medical, a Californian-based biomedical technology company that received $27m in financing in August this year and was named by Fierce Medical Devices as one of its ‘2013 Fierce 15 Device & Diagnostic Companies’, is developing a novel, proprietary bioelectronics medicine platform to treat a variety of inflammation-mediated autoimmune diseases as a safe and effective alternative to using drugs. The therapy consists of three core components: an implanted MicroRegulator, a charger unit that charges the MicroRegulator and an “RxPad” iPad prescription application which sets the dose and frequency of the therapy. The implantable MicroRegulator stimulates the vagus nerve, activating the body’s natural inflammatory reflex to produce a potent systemic anti-inflammatory effect and resulting in dampened inflammation and improved clinical signs and symptoms. 

Sagentia has been brought into the project to develop the iPad App, and to advise on the RF and Bluetooth Low Energy interfaces within the system. Sagentia will develop the app according to the applicable medical device standards in line with the recent guidelines released by the FDA.

 Anthony Arnold, CEO at SetPoint Medical, comments: "We at SetPoint Medical are excited to have the bright minds of the people at Sagentia join us in the development of this revolutionary therapy designed to improve the lives of people with inflammatory diseases.  Together we intend to develop a convenient and novel iOS programming interface that will help facilitate the adoption of this exciting new therapy.”

Dr David Pettigrew, Medical Sector Manager at Sagentia, adds: “SetPoint Medical are truly becoming the front-runners in the emerging field of neuromodulation.  With this new device there is the potential to revolutionise the treatment of chronic inflammatory disease by bringing a real new alternative to traditional drug-based therapy. We see the medically regulated iPad App as a key enabler of this product and the Sagentia team is proud to contribute our experience in wireless systems engineering and medically-regulated App development to the project.”

From a stakeholder perspective, the SetPoint Medical device has the potential to deliver ground-breaking benefits across the healthcare system:

  • For patients: the implanted device has a target to last up to 10 years, replacing the need for routine injections or pills and reducing the risks associated with current treatments;
  • For physicians: the device aims to offer a new and less expensive treatment option for patients suffering from chronic inflammatory diseases, such as rheumatoid arthritis.
  • For payors: the new proposed approach could decrease costs by up to 75%.

The current development program is due to continue through 2014, followed by clinical trials in late 2014/early 2015.  

For further information click here.

---

About Sagentia

Sagentia is a global technology and product development services company. With over 27 years’ experience and more than 10,000 successful projects completed for clients, our scientists and engineers redefine what’s possible and help R&D groups achieve commercial return from their most complex technology projects. We do this across the product development lifecycle, from new concept generation and technology validation, through prototyping and full product development, to transfer to manufacture and sustainability. Our clients range from start-ups through to global market leaders in the medical, industrial, oil & gas and consumer sectors. Sagentia which has over 150 scientists, engineers and market experts is part of the Sagentia Group, with headquarters in Cambridge, UK and offices in London, Guildford, Boston, Houston and Dubai.

For further information visit us at: www.sagentia.com or email info@sagentia.com

About SetPoint Medical

SetPoint Medical is a biomedical technology company developing neuromodulation therapies for patients with inflammatory autoimmune diseases, such as rheumatoid arthritis and Crohn's Disease. SetPoint's approach uses vagus nerve stimulation to activate the Inflammatory Reflex, which produces a potent systemic anti-inflammatory effect. The company's novel platform consists of an implantable miniature neuromodulation device, wireless charger and iPad control application. SetPoint is headquartered in Valencia, Ca., and investors in the company include Morgenthaler Ventures, Foundation Medical Partners and Topspin Partners.

News Source : Sagentia selected as development partner for SetPoint Medical's novel neuromodulation device to treat chronic inflammatory disease

Copy this html code to your website/blog to embed this press release.